GLP-1 drugs can help with weight loss, but they arent without risks
The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs
Researchers dont know exactly why theres a gap between womens and responses to GLP-1s, but a few theories are emerging: The same GLP-1 dose may be more potent for women
Wat is het verschil tussen een Retatrutide Vial en een Retatrutide Disposable Ready-to-Use Pen
List prices after approval may land in the $900 to $1,300 range prior to rebates or discounts
Archived from the original on 12 August 2025